You are here: Home / Our people / Our people / Academic staff list / Dr Susanna Park 

Dr Susanna Park

Senior Lecturer - Physiology
Medicine

Telephone +61 2 9351 0701

Map

Research interests

  • Clinical neurophysiology & nerve excitability
  • Clinical assessment tools
  • Inflammatory & peripheral neuropathies
  • Chemotherapy-induced peripheral neuropathy
  • Motor neuron disorders
  • Cancer survivorship
Back to Top

Current research students

Project title Research student
Early diagnosis of neuropathy in patients with early onset type 2 diabetes and effects of high-intensity aerobic interval training Guyu GU
Chemotherapy-specific neuropathy profiles, risk factors and assessment tools in chemotherapy-induced peripheral neuropathy Hannah TIMMINS
Back to Top

Selected grants

2018

  • Assessment strategies, Treatments and Risk Factors in Neuropathy and Neuromuscular disease; Park S; National Health and Medical Research Council (NHMRC)/Career Development Fellowships.

2016

  • Neuroinflammation in the Peripheral and Central Nervous System: Epidemiological Factors, Vitamin D Status and Functional Relevance; Park S, Taylor B, Mason R, Yiannikas C, Hirani V; Brain Foundation of Australia/Research Grants.
  • In vivo markers of ALS disease activity - linking structure to function; Park S, Kiernan M, Fulham M, Fulham M, Ahmed R, Huynh W, Huynh W, Rowe D; Motor Neurone Disease Research Institute of Australia/Grants in aid.
  • Nodal Function in Peripheral Neuroinflammatory Disorders: Target Antigens, Functional Significance and Treatment Response; Kiernan M, Lin C, Pollard J, Mathey E, Park S, Vucic S; National Health and Medical Research Council (NHMRC)/Project Grants.

2015

  • Chemotherapy-induced Peripheral Neuropathy: Assessment strategies, Treatments and Risk Factors; Goldstein D, Park S, Friedlander M, Kiernan M, Krishnan A, Boyle F, Moalem-Taylor G, Haas M, Cohn R, Farrar M; Cancer Institute New South Wales/Translational Cancer Research Centre.
  • Long-term Nerve Damage in Cancer Survivors: Identification of Risk Factors and Optimal Assessment Strategies; Park S, Krishnan A, Goldstein D, Friedlander M, Lin C, Kwok J, Kwok J, Boyle F, Horvath L, Haas M, Barnes E; National Health and Medical Research Council (NHMRC)/Project Grants.

2014

  • Overseas Biomedical Training (Postdoctoral) Fellowship; Park S; National Health and Medical Research Council (NHMRC)/Early Career Fellowships.

2013

  • Chemotherapy-Induced Neuropathy: Novel Techniques to Assess Nerve Damage and Functional Impairment in Cancer Patients; Park S; Clive & Vera Ramaciotti Foundation/Establishment Grant.
Back to Top

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Park, S., Kiernan, M. (2018). Oxaliplatin and neuropathy: A role for sodium channels. Clinical Neurophysiology, 129(3), 670-671. [More Information]
  • Howells, J., Bostock, H., Park, S., Kiernan, M., Burke, D. (2018). Tracking small sensory nerve action potentials in human axonal excitability studies. Journal of Neuroscience Methods, 298, 45-53. [More Information]
  • Mathey, E., Garg, N., Park, S., Nguyen, T., Baker, S., Yuki, N., Yiannikas, K., Lin, C., Spies, J., Ghaoui, R., Barnett, M., Vucic, S., Pollard, J., Kiernan, M. (2017). Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies. Journal of Neuroimmunology, 309, 41-46. [More Information]
  • Park, S., Kiernan, M., Vucic, S. (2017). Axonal Excitability in Amyotrophic Lateral Sclerosis: Axonal Excitability in ALS. Neurotherapeutics, 14(1), 78-90. [More Information]
  • Timmins, H., Saw, W., Cheah, B., Lin, C., Vucic, S., Ahmed, R., Kiernan, M., Park, S. (2017). Cardiometabolic health and risk of amyotrophic lateral sclerosis. Muscle and Nerve, 56(4), 721-725. [More Information]
  • Makker, P., Duffy, S., Lees, J., Perera, C., Tonkin, R., Butovsky, O., Park, S., Goldstein, D., Moalem-Taylor, G. (2017). Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PloS One, 12(1), 1-24. [More Information]
  • Park, S., Kwok, J., Asher, R., Lee, C., Beale, P., Selle, F., Friedlander, M. (2017). Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinicianreported incidence and severity of neurotoxicity in the ICON7 trial. Annals of Oncology, 28(11), 2733-2740. [More Information]
  • Garg, N., Park, S., Vucic, S., Yiannikas, C., Spies, J., Howells, J., Huynh, W., Matamala, J., Krishnan, A., Pollard, J., Kiernan, M., et al (2017). Differentiating lower motor neuron syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 88(6), 474-483. [More Information]
  • Farrar, M., Park, S., Vucic, S., Carey, K., Turner, B., Gillingwater, T., Swoboda, K., Kiernan, M. (2017). Emerging therapies and challenges in spinal muscular atrophy. Annals of Neurology, 81(3), 355-368. [More Information]
  • Lees, J., Makker, P., Tonkin, R., Abdulla, M., Park, S., Goldstein, D., Moalem-Taylor, G. (2017). Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. European Journal of Cancer, 73, 22-29. [More Information]
  • Shibuya, K., Park, S., Howells, J., Huynh, W., Noto, Y., Shahrizaila, N., Matamala, J., Vucic, S., Kiernan, M. (2017). Laterality of motor cortical function measured by transcranial magnetic stimulation threshold tracking. Muscle and Nerve, 55(3), 424-427. [More Information]
  • Garg, N., Howells, J., Yiannikas, C., Vucic, S., Krishnan, A., Spies, J., Bostock, H., Mathey, E., Pollard, J., Park, S., Kiernan, M. (2017). Motor unit remodelling in multifocal motor neuropathy: The importance of axonal loss. Clinical Neurophysiology, 128(10), 2022-2028. [More Information]
  • Kandula, T., Farrar, M., Kiernan, M., Krishnan, A., Goldstein, D., Horvath, L., Grimison, P., Boyle, F., Baron-Hay, S., Park, S. (2017). Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clinical Neurophysiology, 128(7), 1166-1175. [More Information]
  • McCrary, J., Goldstein, D., Boyle, F., Cox, K., Grimison, P., Kiernan, M., Krishnan, A., Lewis, C., Webber, K., Baron-Hay, S., Horvath, L., Park, S. (2017). Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Supportive Care in Cancer, 25(11), 3485-3493. [More Information]
  • Simon, N., Lagopoulos, J., Paling, S., Pfluger, C., Park, S., Howells, J., Gallagher, T., Kliot, M., Henderson, R., Vucic, S., Kiernan, M. (2017). Peripheral nerve diffusion tensor imaging as a measure of disease progression in ALS. Journal of Neurology, 264(5), 882-890. [More Information]
  • Shibuya, K., Simon, N., Geevasinga, N., Menon, P., Howells, J., Park, S., Huynh, W., Noto, Y., Vucic, S., Kiernan, M. (2017). The evolution of motor cortical dysfunction in amyotrophic lateral sclerosis. Clinical Neurophysiology, 128, 1075-1082. [More Information]
  • Park, S., Baker, M. (2017). Too fast: Rare neuropathic pain state associated with easy activation of NaV1.9. Journal of Neurology, Neurosurgery and Psychiatry, 88(3), 194. [More Information]
  • Garg, N., Yuki, N., Park, S., Barnett, M., Kiernan, M. (2016). Acute bulbar, neck and limb weakness with monospecific anti-GT1a antibody: A rare localized subtype of Guillain-Barre sydnrome. Muscle and Nerve, 53(1), 143-146. [More Information]
  • Park, S., Davare, M., Falla, M., Kennedy, W., Selim, M., Wendelschafer-Crabb, G., Koltzenburg, M. (2016). Fast Adapting Mechanoreceptors are Important for Force Control in Precision Grip but not for Sensorimotor Memory. Journal of Neurophysiology, 115(6), 3156-3161. [More Information]
  • Shibuya, K., Park, S., Geevasinga, N., Menon, P., Howells, J., Simon, N., Huynh, W., Noto, Y., Gotz, J., Kril, J., Vucic, S., Kiernan, M., et al (2016). Motor cortical function determines prognosis in sporadic ALS. Neurology, 87(5), 513-520. [More Information]
  • Kandula, T., Park, S., Cohn, R., Krishnan, A., Farrar, M. (2016). Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge. Cancer Treatment Reviews, 50, 118-128. [More Information]
  • Shibuya, K., Park, S., Geevasinga, N., Huynh, W., Simon, N., Menon, P., Howells, J., Vucic, S., Kiernan, M. (2016). Threshold tracking transcranial magnetic stimulation: Effects of age and gender on motor cortical function. Clinical Neurophysiology, 127(6), 2355-2361. [More Information]
  • Mathey, E., Park, S., Hughes, R., Pollard, J., Armati, P., Barnett, M., Taylor, B., Dyck, J., Kiernan, M., Lin, C. (2015). Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. Journal of Neurology, Neurosurgery and Psychiatry, 86(9), 973-985. [More Information]
  • Park, S., Vucic, S., Cheah, B., Lin, C., Kirby, A., Robledo, K., Zoing, M., Winhammar, J., Kiernan, M. (2015). Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. EBioMedicine, 2(12), 1916-1922. [More Information]
  • Park, S., Sung, J., Tani, J., Kiernan, M., Lin, C. (2015). Reply: biomarkers of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. Brain, 138, 1-2. [More Information]
  • Park, S., Lin, C., Krishnan, A., Simon, N., Bostock, H., Vincent, A., Kiernan, M. (2014). Axonal dysfunction with voltage gated potassium channel complex antibodies. Experimental Neurology, 261, 337-342. [More Information]
  • Farrar, M., Park, S., Krishnan, A., Kiernan, M., Lin, C. (2014). Axonal dysfunction, dysmyelination, and conduction failure in hereditary neuropathy with liability to pressure palsies. Muscle and Nerve, 49(6), 858-865. [More Information]
  • Park, S., Krishnan, A. (2014). Chemotherapy-induced peripheral neuropathy: the end of the beginning? Journal of Neurology, Neurosurgery and Psychiatry, 85(4), 359-359. [More Information]
  • Sung, J., Tani, J., Park, S., Kiernan, M., Lin, C. (2014). Early identification of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. Brain, 137(8), 2155-2163. [More Information]
  • Park, S., Kwok, J., Loy, C., Friedlander, M., Lin, C., Krishnan, A., Lewis, C., Kiernan, M. (2014). Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. BMC Cancer, 14, 1-5. [More Information]
  • Park, S. (2014). The clinical relevance of voltage gated potassium channel (VGKC)-complex antibodies: the story is still unfolding. Journal of Neurology, Neurosurgery and Psychiatry, 85(6), 596-596. [More Information]
  • Park, S., Goldstein, D., Krishnan, A., Lin, C., Friedlander, M., Cassidy, J., Koltzenburg, M., Kiernan, M. (2013). Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA A Cancer Journal for Clinicians, 63(6), 419-437. [More Information]
  • Farrar, M., Park, S., Lin, C., Kiernan, M. (2013). Evolution of peripheral nerve function in humans: novel insights from motor nerve excitability. Journal of Physiology, 591(1), 273-286. [More Information]
  • Bennett, B., Park, S., Lin, C., Friedlander, M., Kiernan, M., Goldstein, D. (2012). Impact of oxaliplatin-induced neuropathy: a patient perspective. Supportive Care in Cancer, 20(11), 2959-2967. [More Information]
  • Krishnan, A., Park, S., Huynh, W., Lin, C., Henderson, R., Kiernan, M. (2012). Impaired energy-dependent processes underlie acute lead neuropathy. Muscle and Nerve, 46(6), 954-956. [More Information]
  • Park, S., Lin, C., Kiernan, M., Koltzenburg, M. (2012). Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology, 78(2), 152. [More Information]
  • Park, S., Lin, C., Kiernan, M. (2012). Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity. Journal of Visualized Experiments, 62, 3439. [More Information]
  • Cheah, B., Lin, C., Park, S., Vucic, S., Krishnan, A., Kiernan, M. (2012). Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clinical Neurophysiology, 123(12), 2460-2467. [More Information]
  • Sung, J., Park, S., Liu, Y., Kwai, N., Arnold, R., Krishnan, A., Lin, C. (2012). Progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes. Diabetes, 61(6), 1592-1598. [More Information]
  • Park, S., Lin, C., Burke, D., Kiernan, M. (2011). Activity-dependent conduction failure: molecular insights. Journal of the Peripheral Nervous System, 16(3), 159-168. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Dose effects of oxaliplatin on persistent and transient na conductances and the development of neurotoxicity. PloS One, 6(4), e18469-e18469. [More Information]
  • Farrar, M., Vucic, S., Lin, C., Park, S., Johnston, H., du Sart, D., Bostock, H., Kiernan, M. (2011). Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. Brain, 134(11), 3185-3197. [More Information]
  • Park, S., Lin, C., Krishnan, A., Friedlander, M., Lewis, C., Kiernan, M. (2011). Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle and Nerve, 43(3), 367-374. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. The Oncologist, 16(5), 708-716. [More Information]
  • Lin, C., Krishnan, A., Park, S., Kiernan, M. (2011). Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. JAMA Neurology, 68(7), 862-869. [More Information]
  • Park, S., Goldstein, D., Lin, C., Krishnan, A., Friedlander, M., Kiernan, M. (2011). Neuroprotection for Oxaliplatin-Induced Neurotoxicity: What Happened to Objective Assessment? Journal of Clinical Oncology, 29(18), e553-e554. [More Information]
  • Lin, C., Lee, M., Park, S., Kiernan, M. (2011). Purple pigments: The pathophysiology of acute porphyric neuropathy. Clinical Neurophysiology, 122(12), 2336-2344. [More Information]
  • Krishnan, A., Park, S., Payne, M., Lin, C., Vucic, S., Kiernan, M. (2011). Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clinical Neurophysiology, 122(1), 194-198. [More Information]
  • Park, S., Lin, C., Krishnan, A., Kiernan, M. (2011). The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects? Cancer Chemotherapy and Pharmacology, 67(5), 1189-1190. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Utilising natural activity to dissect the Pathophysiology of acute oxaliplatin-induced neuropathy. Experimental Neurology, 227(1), 120-127. [More Information]
  • Farrar, M., Lin, C., Krishnan, A., Park, S., Andrews, P., Kiernan, M. (2010). Acute, Reversible Axonal Energy Failure During Stroke-Like Episodes in MELAS. Pediatrics, 126(3), e734-e739. [More Information]
  • Park, S., Goldstein, D., Lin, C., Krishnan, A., Friedlander, M., Kiernan, M. (2009). Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. Journal of Clinical Oncology, 27(8), 1243-1249. [More Information]
  • Krishnan, A., Lin, C., Park, S., Kiernan, M. (2009). Axonal ion channels from bench to bedside: a translational neuroscience perspective. Progress in Neurobiology, 89(3), 288-313. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2009). Oxaliplatin-Induced Lhermitte's Phenomenon as a Manifestation of Severe Generalized Neurotoxicity. Neuro-Oncology, 77(6), 342-348. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2009). Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain, 132(10), 2712-2723. [More Information]
  • Krishnan, A., Lin, C., Park, S., Kiernan, M. (2008). Assessment of nerve excitability in toxic and metabolic neuropathies. Journal of the Peripheral Nervous System, 13(1), 7-26. [More Information]
  • Park, S., Krishnan, A., Lin, C., Goldstein, D., Friedlander, M., Kiernan, M. (2008). Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Current Medicinal Chemistry, 15(29), 3081-3094. [More Information]
  • Gulledge, A., Park, S., Kawaguchi, Y., Stuart, G. (2007). Heterogeneity of phasic cholinergic signaling in neocortical neurons. Journal of Neurophysiology, 97(3), 2215-2229. [More Information]

2018

  • Park, S., Kiernan, M. (2018). Oxaliplatin and neuropathy: A role for sodium channels. Clinical Neurophysiology, 129(3), 670-671. [More Information]
  • Howells, J., Bostock, H., Park, S., Kiernan, M., Burke, D. (2018). Tracking small sensory nerve action potentials in human axonal excitability studies. Journal of Neuroscience Methods, 298, 45-53. [More Information]

2017

  • Mathey, E., Garg, N., Park, S., Nguyen, T., Baker, S., Yuki, N., Yiannikas, K., Lin, C., Spies, J., Ghaoui, R., Barnett, M., Vucic, S., Pollard, J., Kiernan, M. (2017). Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies. Journal of Neuroimmunology, 309, 41-46. [More Information]
  • Park, S., Kiernan, M., Vucic, S. (2017). Axonal Excitability in Amyotrophic Lateral Sclerosis: Axonal Excitability in ALS. Neurotherapeutics, 14(1), 78-90. [More Information]
  • Timmins, H., Saw, W., Cheah, B., Lin, C., Vucic, S., Ahmed, R., Kiernan, M., Park, S. (2017). Cardiometabolic health and risk of amyotrophic lateral sclerosis. Muscle and Nerve, 56(4), 721-725. [More Information]
  • Makker, P., Duffy, S., Lees, J., Perera, C., Tonkin, R., Butovsky, O., Park, S., Goldstein, D., Moalem-Taylor, G. (2017). Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PloS One, 12(1), 1-24. [More Information]
  • Park, S., Kwok, J., Asher, R., Lee, C., Beale, P., Selle, F., Friedlander, M. (2017). Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinicianreported incidence and severity of neurotoxicity in the ICON7 trial. Annals of Oncology, 28(11), 2733-2740. [More Information]
  • Garg, N., Park, S., Vucic, S., Yiannikas, C., Spies, J., Howells, J., Huynh, W., Matamala, J., Krishnan, A., Pollard, J., Kiernan, M., et al (2017). Differentiating lower motor neuron syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 88(6), 474-483. [More Information]
  • Farrar, M., Park, S., Vucic, S., Carey, K., Turner, B., Gillingwater, T., Swoboda, K., Kiernan, M. (2017). Emerging therapies and challenges in spinal muscular atrophy. Annals of Neurology, 81(3), 355-368. [More Information]
  • Lees, J., Makker, P., Tonkin, R., Abdulla, M., Park, S., Goldstein, D., Moalem-Taylor, G. (2017). Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. European Journal of Cancer, 73, 22-29. [More Information]
  • Shibuya, K., Park, S., Howells, J., Huynh, W., Noto, Y., Shahrizaila, N., Matamala, J., Vucic, S., Kiernan, M. (2017). Laterality of motor cortical function measured by transcranial magnetic stimulation threshold tracking. Muscle and Nerve, 55(3), 424-427. [More Information]
  • Garg, N., Howells, J., Yiannikas, C., Vucic, S., Krishnan, A., Spies, J., Bostock, H., Mathey, E., Pollard, J., Park, S., Kiernan, M. (2017). Motor unit remodelling in multifocal motor neuropathy: The importance of axonal loss. Clinical Neurophysiology, 128(10), 2022-2028. [More Information]
  • Kandula, T., Farrar, M., Kiernan, M., Krishnan, A., Goldstein, D., Horvath, L., Grimison, P., Boyle, F., Baron-Hay, S., Park, S. (2017). Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clinical Neurophysiology, 128(7), 1166-1175. [More Information]
  • McCrary, J., Goldstein, D., Boyle, F., Cox, K., Grimison, P., Kiernan, M., Krishnan, A., Lewis, C., Webber, K., Baron-Hay, S., Horvath, L., Park, S. (2017). Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Supportive Care in Cancer, 25(11), 3485-3493. [More Information]
  • Simon, N., Lagopoulos, J., Paling, S., Pfluger, C., Park, S., Howells, J., Gallagher, T., Kliot, M., Henderson, R., Vucic, S., Kiernan, M. (2017). Peripheral nerve diffusion tensor imaging as a measure of disease progression in ALS. Journal of Neurology, 264(5), 882-890. [More Information]
  • Shibuya, K., Simon, N., Geevasinga, N., Menon, P., Howells, J., Park, S., Huynh, W., Noto, Y., Vucic, S., Kiernan, M. (2017). The evolution of motor cortical dysfunction in amyotrophic lateral sclerosis. Clinical Neurophysiology, 128, 1075-1082. [More Information]
  • Park, S., Baker, M. (2017). Too fast: Rare neuropathic pain state associated with easy activation of NaV1.9. Journal of Neurology, Neurosurgery and Psychiatry, 88(3), 194. [More Information]

2016

  • Garg, N., Yuki, N., Park, S., Barnett, M., Kiernan, M. (2016). Acute bulbar, neck and limb weakness with monospecific anti-GT1a antibody: A rare localized subtype of Guillain-Barre sydnrome. Muscle and Nerve, 53(1), 143-146. [More Information]
  • Park, S., Davare, M., Falla, M., Kennedy, W., Selim, M., Wendelschafer-Crabb, G., Koltzenburg, M. (2016). Fast Adapting Mechanoreceptors are Important for Force Control in Precision Grip but not for Sensorimotor Memory. Journal of Neurophysiology, 115(6), 3156-3161. [More Information]
  • Shibuya, K., Park, S., Geevasinga, N., Menon, P., Howells, J., Simon, N., Huynh, W., Noto, Y., Gotz, J., Kril, J., Vucic, S., Kiernan, M., et al (2016). Motor cortical function determines prognosis in sporadic ALS. Neurology, 87(5), 513-520. [More Information]
  • Kandula, T., Park, S., Cohn, R., Krishnan, A., Farrar, M. (2016). Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge. Cancer Treatment Reviews, 50, 118-128. [More Information]
  • Shibuya, K., Park, S., Geevasinga, N., Huynh, W., Simon, N., Menon, P., Howells, J., Vucic, S., Kiernan, M. (2016). Threshold tracking transcranial magnetic stimulation: Effects of age and gender on motor cortical function. Clinical Neurophysiology, 127(6), 2355-2361. [More Information]

2015

  • Mathey, E., Park, S., Hughes, R., Pollard, J., Armati, P., Barnett, M., Taylor, B., Dyck, J., Kiernan, M., Lin, C. (2015). Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. Journal of Neurology, Neurosurgery and Psychiatry, 86(9), 973-985. [More Information]
  • Park, S., Vucic, S., Cheah, B., Lin, C., Kirby, A., Robledo, K., Zoing, M., Winhammar, J., Kiernan, M. (2015). Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. EBioMedicine, 2(12), 1916-1922. [More Information]
  • Park, S., Sung, J., Tani, J., Kiernan, M., Lin, C. (2015). Reply: biomarkers of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. Brain, 138, 1-2. [More Information]

2014

  • Park, S., Lin, C., Krishnan, A., Simon, N., Bostock, H., Vincent, A., Kiernan, M. (2014). Axonal dysfunction with voltage gated potassium channel complex antibodies. Experimental Neurology, 261, 337-342. [More Information]
  • Farrar, M., Park, S., Krishnan, A., Kiernan, M., Lin, C. (2014). Axonal dysfunction, dysmyelination, and conduction failure in hereditary neuropathy with liability to pressure palsies. Muscle and Nerve, 49(6), 858-865. [More Information]
  • Park, S., Krishnan, A. (2014). Chemotherapy-induced peripheral neuropathy: the end of the beginning? Journal of Neurology, Neurosurgery and Psychiatry, 85(4), 359-359. [More Information]
  • Sung, J., Tani, J., Park, S., Kiernan, M., Lin, C. (2014). Early identification of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. Brain, 137(8), 2155-2163. [More Information]
  • Park, S., Kwok, J., Loy, C., Friedlander, M., Lin, C., Krishnan, A., Lewis, C., Kiernan, M. (2014). Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. BMC Cancer, 14, 1-5. [More Information]
  • Park, S. (2014). The clinical relevance of voltage gated potassium channel (VGKC)-complex antibodies: the story is still unfolding. Journal of Neurology, Neurosurgery and Psychiatry, 85(6), 596-596. [More Information]

2013

  • Park, S., Goldstein, D., Krishnan, A., Lin, C., Friedlander, M., Cassidy, J., Koltzenburg, M., Kiernan, M. (2013). Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA A Cancer Journal for Clinicians, 63(6), 419-437. [More Information]
  • Farrar, M., Park, S., Lin, C., Kiernan, M. (2013). Evolution of peripheral nerve function in humans: novel insights from motor nerve excitability. Journal of Physiology, 591(1), 273-286. [More Information]

2012

  • Bennett, B., Park, S., Lin, C., Friedlander, M., Kiernan, M., Goldstein, D. (2012). Impact of oxaliplatin-induced neuropathy: a patient perspective. Supportive Care in Cancer, 20(11), 2959-2967. [More Information]
  • Krishnan, A., Park, S., Huynh, W., Lin, C., Henderson, R., Kiernan, M. (2012). Impaired energy-dependent processes underlie acute lead neuropathy. Muscle and Nerve, 46(6), 954-956. [More Information]
  • Park, S., Lin, C., Kiernan, M., Koltzenburg, M. (2012). Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology, 78(2), 152. [More Information]
  • Park, S., Lin, C., Kiernan, M. (2012). Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity. Journal of Visualized Experiments, 62, 3439. [More Information]
  • Cheah, B., Lin, C., Park, S., Vucic, S., Krishnan, A., Kiernan, M. (2012). Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clinical Neurophysiology, 123(12), 2460-2467. [More Information]
  • Sung, J., Park, S., Liu, Y., Kwai, N., Arnold, R., Krishnan, A., Lin, C. (2012). Progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes. Diabetes, 61(6), 1592-1598. [More Information]

2011

  • Park, S., Lin, C., Burke, D., Kiernan, M. (2011). Activity-dependent conduction failure: molecular insights. Journal of the Peripheral Nervous System, 16(3), 159-168. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Dose effects of oxaliplatin on persistent and transient na conductances and the development of neurotoxicity. PloS One, 6(4), e18469-e18469. [More Information]
  • Farrar, M., Vucic, S., Lin, C., Park, S., Johnston, H., du Sart, D., Bostock, H., Kiernan, M. (2011). Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. Brain, 134(11), 3185-3197. [More Information]
  • Park, S., Lin, C., Krishnan, A., Friedlander, M., Lewis, C., Kiernan, M. (2011). Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle and Nerve, 43(3), 367-374. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. The Oncologist, 16(5), 708-716. [More Information]
  • Lin, C., Krishnan, A., Park, S., Kiernan, M. (2011). Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. JAMA Neurology, 68(7), 862-869. [More Information]
  • Park, S., Goldstein, D., Lin, C., Krishnan, A., Friedlander, M., Kiernan, M. (2011). Neuroprotection for Oxaliplatin-Induced Neurotoxicity: What Happened to Objective Assessment? Journal of Clinical Oncology, 29(18), e553-e554. [More Information]
  • Lin, C., Lee, M., Park, S., Kiernan, M. (2011). Purple pigments: The pathophysiology of acute porphyric neuropathy. Clinical Neurophysiology, 122(12), 2336-2344. [More Information]
  • Krishnan, A., Park, S., Payne, M., Lin, C., Vucic, S., Kiernan, M. (2011). Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clinical Neurophysiology, 122(1), 194-198. [More Information]
  • Park, S., Lin, C., Krishnan, A., Kiernan, M. (2011). The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects? Cancer Chemotherapy and Pharmacology, 67(5), 1189-1190. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Utilising natural activity to dissect the Pathophysiology of acute oxaliplatin-induced neuropathy. Experimental Neurology, 227(1), 120-127. [More Information]

2010

  • Farrar, M., Lin, C., Krishnan, A., Park, S., Andrews, P., Kiernan, M. (2010). Acute, Reversible Axonal Energy Failure During Stroke-Like Episodes in MELAS. Pediatrics, 126(3), e734-e739. [More Information]

2009

  • Park, S., Goldstein, D., Lin, C., Krishnan, A., Friedlander, M., Kiernan, M. (2009). Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. Journal of Clinical Oncology, 27(8), 1243-1249. [More Information]
  • Krishnan, A., Lin, C., Park, S., Kiernan, M. (2009). Axonal ion channels from bench to bedside: a translational neuroscience perspective. Progress in Neurobiology, 89(3), 288-313. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2009). Oxaliplatin-Induced Lhermitte's Phenomenon as a Manifestation of Severe Generalized Neurotoxicity. Neuro-Oncology, 77(6), 342-348. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2009). Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain, 132(10), 2712-2723. [More Information]

2008

  • Krishnan, A., Lin, C., Park, S., Kiernan, M. (2008). Assessment of nerve excitability in toxic and metabolic neuropathies. Journal of the Peripheral Nervous System, 13(1), 7-26. [More Information]
  • Park, S., Krishnan, A., Lin, C., Goldstein, D., Friedlander, M., Kiernan, M. (2008). Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Current Medicinal Chemistry, 15(29), 3081-3094. [More Information]

2007

  • Gulledge, A., Park, S., Kawaguchi, Y., Stuart, G. (2007). Heterogeneity of phasic cholinergic signaling in neocortical neurons. Journal of Neurophysiology, 97(3), 2215-2229. [More Information]
Back to Top

To update your profile click here. For support on your academic profile contact .